MA46176A - Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci - Google Patents

Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci

Info

Publication number
MA46176A
MA46176A MA046176A MA46176A MA46176A MA 46176 A MA46176 A MA 46176A MA 046176 A MA046176 A MA 046176A MA 46176 A MA46176 A MA 46176A MA 46176 A MA46176 A MA 46176A
Authority
MA
Morocco
Prior art keywords
azetidin
triazolo
compositions
methods
pyridinyl compounds
Prior art date
Application number
MA046176A
Other languages
English (en)
Inventor
Limin Cheng
Yun-Xing Cheng
Simon Charles Goodacre
Rongbao Hua
F Anthony Romero
Mark Zak
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA46176A publication Critical patent/MA46176A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA046176A 2016-09-06 2017-09-02 Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci MA46176A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016098215 2016-09-06

Publications (1)

Publication Number Publication Date
MA46176A true MA46176A (fr) 2019-07-17

Family

ID=59761965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046176A MA46176A (fr) 2016-09-06 2017-09-02 Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci

Country Status (19)

Country Link
US (3) US20190202822A1 (fr)
EP (2) EP4198036A1 (fr)
JP (1) JP7050761B2 (fr)
KR (1) KR20190045302A (fr)
CN (1) CN109890817B (fr)
AU (1) AU2017324281A1 (fr)
BR (1) BR112019004486A2 (fr)
CA (1) CA3035712A1 (fr)
CL (1) CL2019000568A1 (fr)
CO (1) CO2019002171A2 (fr)
CR (1) CR20190118A (fr)
IL (1) IL265153A (fr)
MA (1) MA46176A (fr)
MX (1) MX2019002627A (fr)
PE (1) PE20190632A1 (fr)
PH (1) PH12019500478A1 (fr)
RU (1) RU2019109570A (fr)
SG (1) SG11201901954XA (fr)
WO (1) WO2018046409A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3986899A1 (fr) * 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Inhibiteurs éther-aryl-pyrazolopyrimidine de kinases jak et leurs utilisations
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024148186A1 (fr) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Polymorphes d'un inhibiteur de jak1/tyk2 et leurs utilisations
WO2024148184A1 (fr) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Composés et procédés pour la préparation d'inhibiteurs de jak

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP0842195A1 (fr) 1995-07-06 1998-05-20 Zeneca Limited Inhibiteurs peptidiques de la fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Dérivés de purine pour le traitement de l'ischémie
ES2271365T3 (es) 2001-12-20 2007-04-16 Bayer Healthcare Ag Derivados de 1,4-dihidro-1,4-difenilpiridina.
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
CN102131389A (zh) * 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
WO2010010184A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010141796A2 (fr) 2009-06-05 2010-12-09 Cephalon, Inc. Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PL3231801T3 (pl) * 2013-05-17 2019-07-31 Incyte Corporation Sol bipirazolu jako inhibitor jak
EP3041841B1 (fr) 2013-09-05 2019-06-05 F. Hoffmann-La Roche AG Composé de triazolopyridine, compositions et procédés d'utilisation associés
EP3265464A1 (fr) * 2015-03-04 2018-01-10 F. Hoffmann-La Roche AG Composés de triazolopyridine, et procédés d'utilisation de ceux-ci

Also Published As

Publication number Publication date
BR112019004486A2 (pt) 2019-05-28
AU2017324281A1 (en) 2019-03-21
PH12019500478A1 (en) 2019-12-02
CA3035712A1 (fr) 2018-03-15
JP7050761B2 (ja) 2022-04-08
RU2019109570A (ru) 2020-10-08
EP4198036A1 (fr) 2023-06-21
JP2019526593A (ja) 2019-09-19
EP3510030A1 (fr) 2019-07-17
CN109890817B (zh) 2022-06-17
CR20190118A (es) 2019-04-30
US20190202822A1 (en) 2019-07-04
KR20190045302A (ko) 2019-05-02
CN109890817A (zh) 2019-06-14
US20230242530A1 (en) 2023-08-03
IL265153A (en) 2019-05-30
MX2019002627A (es) 2019-10-30
US20200270248A1 (en) 2020-08-27
PE20190632A1 (es) 2019-04-26
SG11201901954XA (en) 2019-04-29
CO2019002171A2 (es) 2019-05-21
EP3510030B1 (fr) 2023-03-22
RU2019109570A3 (fr) 2020-10-08
WO2018046409A1 (fr) 2018-03-15
CL2019000568A1 (es) 2019-07-12

Similar Documents

Publication Publication Date Title
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
EP3374494A4 (fr) Compositions crispr et leurs méthodes d'utilisation pour la thérapie génique
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
SI3555097T1 (sl) Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
HK1250645A1 (zh) 取代的2，3-二氫咪唑並[1，2-c]喹唑啉類化合物的用途
HUE057317T2 (hu) Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
MA46176A (fr) Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci
HK1259372A1 (zh) 治療化合物、其組合物及使用方法
EP3512554A4 (fr) Compositions plaquettaires et procédés pour l'administration d'agents thérapeutiques
HK1247203A1 (zh) 取代的咪唑並[1，2-α]吡啶-2-基胺化合物及其藥物組合物和使用方法
MA47167A (fr) Composés pyrazolopyrimidine et leurs procédés d'utilisation
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
HUS2200054I1 (hu) 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése
DK3500571T3 (da) Imidazo[1,2-a]pyridinforbindelser, sammensætninger omfattende disse, fremgangsmåder til behandling af sygdomme ved hjælp af disse og fremgangsmåder til fremstilling heraf
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
EP3689875A4 (fr) Utilisation de triazolopyrimidine, de composés de triazolopyridine et d'une composition de ceux-ci pour le traitement de maladies médiées par prc2
SG10201908881PA (en) Fused bicyclic compounds for the treatment of disease
EP3122381A4 (fr) Utilisation d'antagonistes de la kinase 1 apparentée au récepteur de l'activine (alk-1) dans le traitement du cancer
EP3475442A4 (fr) Composés d'acide 12(s)-hydroxyéicosatriénoïque et leur utilisation comme agents thérapeutiques
TH182466B (th) สารกลุ่ม 1เอช-ไพร์โรโล[2,3-ซี]ไพริดิน-7(6เอช)-โอน และไพราโซโล[3,4-ซี] ไพริดิน-7(6เอช)-โอน ที่เป็นตัวยับยั้งของโปรตีน bet